FibroBiologics, Inc. FBLG on Nasdaq
This company's Exchange Act registration has been revoked
This company's Exchange Act registration as a Municipal Advisor has been revoked
This company's Exchange Act registration as a Municipal Advisor has been cancelled
[+] Company Information
CIK:
0001958777
0001958777
EIN:
86-3329066
86-3329066
LEI:
(CF Office: 03 Life Sciences)
Business address:
455 E. MEDICAL CENTER BLVD, SUITE 300, HOUSTON, TX, 77598
Phone: 281-671-5150
455 E. MEDICAL CENTER BLVD, SUITE 300, HOUSTON, TX, 77598
Phone: 281-671-5150
Mailing address:
455 E. MEDICAL CENTER BLVD SUITE 300, SUITE 300, HOUSTON, TX, 77598
455 E. MEDICAL CENTER BLVD SUITE 300, SUITE 300, HOUSTON, TX, 77598
Category:
Emerging growth company
Emerging growth company
Former names:
- FibroBiologics Inc. - filings through 2024-02-06
Filings:
129 EDGAR filings since January 31, 2023
129 EDGAR filings since January 31, 2023
Get insider transactions
for this issuer
Get insider transactions
for this reporting owner
Latest Filings (excluding insider transactions)
- March 31, 2025 - 10-K: Annual report for year ending December 31, 2024Open documentClick to Open document FilingOpen filingClick to Open filing
- February 12, 2025 - SCHEDULE 13G: Schedule filed by certain investors to report beneficial ownership of more than 5% of a class of equity securitiesOpen documentClick to Open document FilingOpen filingClick to Open filing
- February 10, 2025 - EFFECT: Notice of Effectiveness Open documentClick to Open document FilingOpen filingClick to Open filing
- February 7, 2025 - 8-K: Current report Open documentClick to Open document FilingOpen filingClick to Open filing
- 3.02 - Unregistered Sales of Equity Securities
- 9.01 - Financial Statements and Exhibits
- February 6, 2025 - CORRESP: Correspondence Open documentClick to Open document FilingOpen filingClick to Open filing
Selected Filings
[+] 8-K (current reports)
- February 7, 2025 - 8-K: Current report Open documentClick to Open document FilingOpen filingClick to Open filing
- 3.02 - Unregistered Sales of Equity Securities
- 9.01 - Financial Statements and Exhibits
- January 24, 2025 - 8-K: Current report Open documentClick to Open document FilingOpen filingClick to Open filing
- 5.02 - Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers
- 9.01 - Financial Statements and Exhibits
- December 31, 2024 - 8-K: Current report Open documentClick to Open document FilingOpen filingClick to Open filing
- 1.01 - Entry into a Material Definitive Agreement
- 2.03 - Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
- 3.02 - Unregistered Sales of Equity Securities
- 5.02 - Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers
- 7.01 - Regulation FD Disclosure
- 9.01 - Financial Statements and Exhibits
- December 23, 2024 - 8-K: Current report Open documentClick to Open document FilingOpen filingClick to Open filing
- 1.01 - Entry into a Material Definitive Agreement
- 2.03 - Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
- 3.02 - Unregistered Sales of Equity Securities
- 7.01 - Regulation FD Disclosure
- 9.01 - Financial Statements and Exhibits
- December 20, 2024 - 8-K: Current report Open documentClick to Open document FilingOpen filingClick to Open filing
- 1.01 - Entry into a Material Definitive Agreement
- 1.02 - Termination of a Material Definitive Agreement
- 3.02 - Unregistered Sales of Equity Securities
- 9.01 - Financial Statements and Exhibits
[+] 10-K (annual reports) and 10-Q (quarterly reports)
- March 31, 2025 - 10-K: Annual report for year ending December 31, 2024Open documentClick to Open document FilingOpen filingClick to Open filing
- November 12, 2024 - 10-Q: Quarterly report for quarter ending September 30, 2024Open documentClick to Open document FilingOpen filingClick to Open filing
- August 7, 2024 - 10-Q: Quarterly report for quarter ending June 30, 2024Open documentClick to Open document FilingOpen filingClick to Open filing
- May 14, 2024 - 10-Q: Quarterly report for quarter ending March 31, 2024Open documentClick to Open document FilingOpen filingClick to Open filing
[+] Proxy (annual meeting) and information statements
- July 8, 2024 - DEF 14A: Other definitive proxy statements Open documentClick to Open document FilingOpen filingClick to Open filing
- June 27, 2024 - PRE 14A: Other preliminary proxy statements Open documentClick to Open document FilingOpen filingClick to Open filing
[+] Ownership disclosures
- Insider transactions
- March 28, 2025 - 4: Statement of changes in beneficial ownership of securities Open documentClick to Open document FilingOpen filingClick to Open filing
- March 28, 2025 - 4: Statement of changes in beneficial ownership of securities Open documentClick to Open document FilingOpen filingClick to Open filing
- March 28, 2025 - 4: Statement of changes in beneficial ownership of securities Open documentClick to Open document FilingOpen filingClick to Open filing
- Beneficial ownership (Schedule 13D and 13G)
- February 12, 2025 - SCHEDULE 13G: Schedule filed by certain investors to report beneficial ownership of more than 5% of a class of equity securitiesOpen documentClick to Open document FilingOpen filingClick to Open filing
- January 30, 2025 - SCHEDULE 13G/A: Schedule filed by certain investors to report beneficial ownership of more than 5% of a class of equity securities - amendmentOpen documentClick to Open document FilingOpen filingClick to Open filing
- January 29, 2025 - SCHEDULE 13G: Schedule filed by certain investors to report beneficial ownership of more than 5% of a class of equity securitiesOpen documentClick to Open document FilingOpen filingClick to Open filing
Filings
| Form type | Form description | Filing date | Reporting date |
|---|
0
Showing 1 to 48 of 129 entries
Data source:
CIK0001958777.json
There is no filings data for
this organization
Investor Resources
How to Use EDGAR
Learn how to use EDGAR to research public filings by public companies, mutual funds, ETFs, some annuities, and more.
Before you Invest, Investor.gov
Get answers to your investing questions from the SEC's website dedicated to retail investors
